Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486899 · ClinicalTrials.gov registry record · Phase 2
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT03486899 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 197 participants.
The verdict
NCT03486899, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).
Interventions
- OTHER Placebo
- DRUG BMS-986036
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2021-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03486899
The ClinicalTrials.gov registry entry for NCT03486899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03486899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03486899 about?
NCT03486899 is a clinical study titled "A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis". This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).
What is the current status of trial NCT03486899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2018-06-19. Estimated completion is 2021-08-17.
What interventions are being tested in trial NCT03486899?
The interventions under investigation include: Placebo (OTHER), BMS-986036 (DRUG).
Who is sponsoring clinical trial NCT03486899?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.